RxDoctor Payments Data

Robert Mann, MD

Internal Medicine · Florence, ALNPI 1548371347

Payments from drug & device makers

$2,409in general payments, 2019–2025

Across 154 payments — averaging $15.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$415
  • Pfizer$390
  • Boehringer Ingelheim$366
  • Lilly USA, LLC$152
  • Amarin Pharma, Inc.$144
  • AbbVie$104
  • plus $838 from 16 others

What the payments were for

  • Food & beverage$2,409100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,409 in reported general payments places this provider in the 70th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$261,434
Medicare patients
375
Services billed
4,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban291$261,606
MounjaroTirzepatide192$226,096
OzempicSemaglutide79$85,031
JardianceEmpagliflozin77$80,274
JanuviaSitagliptin Phosphate67$67,023
XareltoRivaroxaban75$61,414
FarxigaDapagliflozin Propanediol101$59,591
CreonLipase/Protease/Amylase41$49,154
TrulicityDulaglutide29$35,503
EntrestoSacubitril/Valsartan34$26,457
MyrbetriqMirabegron37$25,099
Janumet XrSitagliptin Phos/Metformin Hcl28$18,983
Rosuvastatin Calcium616$13,900
GemtesaVibegron24$13,667
RybelsusSemaglutide13$13,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$390$261,606291 claims
Lilly USA, LLCMounjaro, Trulicity$152$261,599221 claims
MerckJanuvia, Janumet Xr, Lagevrio (Eua), Dulera, Janumet$415$119,880142 claims
Novo NordiskOzempic, Rybelsus$83$98,18492 claims
Boehringer IngelheimJardiance$366$80,27477 claims
AstraZenecaFarxiga, Brilinta$14$69,403117 claims
Johnson & JohnsonXarelto$77$61,41475 claims
AbbVieCreon, Linzess, Synthroid$104$61,138111 claims
NovartisEntresto$103$26,45734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Florence

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →